Exchange: NASDAQ·Updated 02:17 PM EDT
News
all
press releases
United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark
UTHR tops Q2 EPS estimates, misses revenues, while advancing Tyvaso and ralinepag programs that reshape future growth.
Zacks
More News
Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics
The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks
MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of -200.00% and +2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease
MannKind stock rose after the FDA approved Furoscix ReadyFlow, as the company also announced a $50 million private placement financing.read more...
Benzinga
MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost
FDA approved MannKind’s Furoscix ReadyFlow on Friday.
Stocktwits
MNKD Stock Rises Premarket As FDA Verdict Nears – Retail Optimism Builds
The FDA is expected to announce its decision on MannKind’s sNDA on July 26, 2026.
Stocktwits
What This MannKind Filing Reveals About Three Years of Underperformance
Key PointsThis MannKind insider filing details the disposition of 46,795 shares...
Nasdaq News: Markets
What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk
Key PointsThe transactions involved 76,880 shares with a total value of about $313,000, based on a weighted average execution price of $4.07 per share...
Nasdaq News: Markets
What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Million
Key PointsDavid Thomson disposed of 123,000 shares at $4.08 per share, representing a total transaction value of about $500,000...
Nasdaq News: Markets
Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Risk
Key PointsThis filing reported an insider's total disposition of 65,808 shares for an estimated value of $269,000 based on the July 15, 2026 market close...
Nasdaq News: Markets

Advertisement|Remove ads.